Real-world evaluation of the christie symptom inventory-lung cancer (CSI-lung) electronic patient-reported outcome measure: validity, reliability, responsiveness, and patient experiences [0.03%]
Christie症状量表-肺癌（CSI-肺）电子患者报告结局测量的现实世界评估：有效性和可靠性、反应度和患者体验
Thitikorn Nuamek,Kuan Liao,Ashleigh Ward et al.
Thitikorn Nuamek et al.
Objectives: The routine use of electronic patient-reported outcome measures (ePROMs) in oncology is expanding internationally, yet uncertainty remains regarding the most suitable tool for routine care. The Christie Sympto...
Clinical characteristics and management of Li-Fraumeni syndrome-associated lung cancer [0.03%]
利弗莫恩综合征相关肺癌的临床特征和管理
Kota Ishioka,Makoto Nishio,Hironori Ninomiya et al.
Kota Ishioka et al.
Li-Fraumeni syndrome (LFS), caused by pathogenic germline TP53 variants, is increasingly recognized as a predisposition to lung adenocarcinoma (LUAD); however, its clinical features remain insufficiently defined. Patients diagnosed with LFS...
Immune signatures in NSCLC associated pleural effusions and implications for prognosis [0.03%]
非小细胞肺癌相关性胸腔积液中的免疫特征及其预后的潜在价值
Matilde Lombardi,Michael Gerckens,Gülümser Hale Alkan et al.
Matilde Lombardi et al.
Background: Pleural effusions (PEs) are frequent in patients with non-small cell lung cancer (NSCLC) and have prognostic implications. Detection of malignant cells in pleural fluid defines metastatic disease. However, PE ...
DAFNet: A multi-modal deep learning model based on whole-lung CT for the automated prediction of the air space spread of lung adenocarcinoma [0.03%]
基于全肺CT的多模态深度学习模型自动生成预测肺癌病理三期分期
Jirui Guo,Shizheng Qiu,Huanyu You et al.
Jirui Guo et al.
Spread through air spaces (STAS) is a characteristic invasive pattern of lung adenocarcinoma (LUAD), which is associated with a high recurrence rate and poor prognosis. This research introduced the automatic deep learning multimodal detecti...
Coordinated microbial-inflammatory associations in never-smoking lung cancer [0.03%]
从不吸烟的肺癌患者的微生物-炎症相关性研究
Pushpa Dhilipkannah,Feng Jiang
Pushpa Dhilipkannah
Background: While smoking is the leading cause of lung cancer, the increasing incidence among never-smokers is a growing concern, highlighting non-tobacco-related mechanisms of carcinogenesis. Emerging evidence suggests t...
BRAF fusions define therapeutic vulnerability and tyrosine kinase inhibitor resistance in non-small cell lung cancer [0.03%]
BRAF融合基因定义了非小细胞肺癌的治疗弱点和酪氨酸激酶抑制剂耐药性
Kai Wang,Chao Yi,Xiong Ning et al.
Kai Wang et al.
Background: BRAF fusions are rare but clinically relevant oncogenic events in non-small cell lung cancer (NSCLC), yet their molecular characteristics and optimal management remain unclear. ...
The limits of pooled evidence in early-stage NSCLC: are we comparing treatments or patients? [0.03%]
早期NSCLC中汇总证据的局限性：我们是在比较治疗手段还是患者？
Peter S N van Rossum,Famke L Schneiders,Suresh Senan
Peter S N van Rossum
Associated factors regarding systemic anticancer therapy use prior to death among patients with metastatic non-small cell lung cancer: A multicentre retrospective cohort study [0.03%]
转移性非小细胞肺癌患者临终前使用系统性抗癌治疗的相关因素：一项多中心回顾性队列研究
Kiki Mokkenstorm,Salomé van Beusekom,Camille Breukhoven et al.
Kiki Mokkenstorm et al.
Background: Systemic anticancer therapy (SACT) near the end of life among patients with metastatic non-small cell lung cancer (NSCLC) is considered a population-level quality indicator of potentially inappropriate end-of-...
Low baseline cGAS expression is associated with longer progression-free survival in patients with pleural mesothelioma [0.03%]
低基线cGAS表达与恶性胸膜间皮瘤患者的无进展生存期较长有关
Antoine Torchiat,Karina Silina,Arya Ashok Nair et al.
Antoine Torchiat et al.
Introduction: The cyclic GMP-AMP synthase (cGAS)/STING pathway, a central DNA-sensing mechanism, is known to activate anti-tumor immune response but may also promote tumor progression when chronically activated. Given the...
Comparative efficacy of taletrectinib versus first-generation TKIs in TKI-naïve ROS1+ non-small cell lung cancer: A matching-adjusted indirect comparison [0.03%]
与第一代TKIs相比，taletrectinib治疗ROS1阳性且未接受过TKI治疗的非小细胞肺癌患者的疗效：匹配调整后的间接对比研究
Misako Nagasaka,Geoffrey Liu,Maurice Pérol et al.
Misako Nagasaka et al.
Background: Taletrectinib is a next-generation, selective ROS1 tyrosine kinase inhibitor (TKI) approved for the treatment of advanced ROS1+ non-small cell lung cancer (NSCLC). In the absence of head-to-head trials compari...